With Activist Investors Looming, Genzyme Takes Preventive Steps
Executive Summary
An eventful week at Genzyme concluded with two developments that could keep activist investors and the potential for a proxy fight at bay - a mutual cooperation agreement with a top institutional investor and the hiring of a senior vice president of global product quality
You may also be interested in...
Genzyme To Contract Out Fill And Finish Responsibilities For Four Drugs To Hospira
Initial Cerezyme and Fabrazyme production stays at Allston Landing, but final stages go to Genzyme's Ireland facility or a Hospira plant.
FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification
A Form 483 posted online by FDA following a five-week inspection of the Allston Landing manufacturing plant cites 49 separate concerns.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011